Psychedelic Drug Stocks Explode After Trump's FDA Fast-Track Executive Order

Key Takeaways

Table of Contents

President Trump issued an executive directive Saturday requiring the FDA to expedite approval processes for psychedelic-based mental health treatments
AtaiBeckley stock surged 28% in early Monday trading; Compass Pathways climbed 26%
The presidential order introduces Commissioner’s National Priority Vouchers for drugs holding “breakthrough therapy” designation, slashing review periods from 6–10 months to just 1–2 months
The order specifically names ibogaine, currently a Schedule I controlled substance under investigation for treating opioid dependency
Federal authorities will dedicate $50 million toward ibogaine research initiatives

On Saturday, President Trump issued an executive order mandating the Food and Drug Administration accelerate its evaluation process for psychedelic-based medications. The presidential directive bears the title “Accelerating Medical Treatments for Serious Mental Illness.”

[[EMBED_0]]

The mandate encompasses therapeutic approaches for conditions such as treatment-resistant depression, post-traumatic stress disorder, and substance use disorders.

FDA Commissioner Marty Makary indicated that regulatory determinations on certain compounds could arrive as early as the coming summer months.

The presidential action compresses standard evaluation timelines from 6–10 months to just 1–2 months for medications already carrying “breakthrough therapy” status. The mechanism involves Commissioner’s National Priority Vouchers.

Shares of companies developing psychedelic therapeutics experienced dramatic gains during Monday’s premarket session. AtaiBeckley skyrocketed 28%, Compass Pathways advanced 26%, GH Research added 19%, Definium Therapeutics increased 15%, Cybin climbed approximately 15%, and Enveric BioSciences gained 7%.

COMPASS Pathways plc, CMPS

AtaiBeckley currently commands a market capitalization of approximately $1.5 billion, positioning it among the largest publicly traded entities in the psychedelic pharmaceutical sector.

Biotech Sector Rallies Following Presidential Action

The company’s primary candidate, BPL-003, represents a nasal spray formulation designed for treatment-resistant depression. Phase 3 clinical trials are scheduled to commence later this quarter.

Compass Pathways, a United Kingdom-based biotechnology firm, is advancing COMP360, a synthetic psilocybin compound. The drug candidate is progressing through late-stage clinical trials for treatment-resistant depression and has secured FDA Breakthrough Therapy designation.

The executive directive explicitly mentions ibogaine, a psychedelic compound extracted from an African shrub. Under current U.S. law, ibogaine holds Schedule I classification, indicating authorities consider it lacking legitimate medical applications.

Researchers are investigating ibogaine as a potential intervention for opioid addiction. The order directs federal regulators to facilitate access through the Right to Try Act, legislation Trump signed into law in 2018.

Clinical data has documented ibogaine’s association with cardiac toxicity risks, a concern that has generated regulatory scrutiny.

Federal Investment and Industry Expert Commentary

President Trump announced the federal government will commit $50 million to support ibogaine research programs.

Jefferies analyst Andrew Tsai characterized the order as an “official stamp of validation to the class,” emphasizing it demonstrates genuine governmental backing.

RBC analyst Brian Abrahams stated the executive action “is a substantial step towards diminishing regulatory risk” surrounding psychedelic medications.

Health and Human Services Secretary Robert F. Kennedy Jr. has vocally endorsed ibogaine as an alternative therapeutic option for depression and additional psychiatric conditions.

Legislators across the political spectrum have expressed intentions to advance legislative measures expanding access to psychedelic treatment modalities.

FDA Commissioner Makary verified the agency stands ready to implement rapid action under the new presidential directive.

✨ Limited Time Offer